Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7

Breast Cancer Research and Treatment

Volumn 55, Issue 1, 1999, Pages 73-83

  Leung, Lai K ^a   Wang, Thomas T Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bax; Bcl 2; Breast; Chemotherapy; Estradiol

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DOXORUBICIN; ESTRADIOL; ETOPOSIDE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CAMPTOTHECIN; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0032854766     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006190802590     Document Type: Article

References (25)

1. 1. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972
2. 2. Carson DA, Ribeiro JM: Apoptosis and disease. Lancet 341: 1251-1254, 1993
3. 3. Mikulski SM: Pathogenesis of cancer in view of mutually opposing apoptotic and anti-apoptotic growth signals (Review). Int J Onc 4: 1257-1263, 1994
4. 4. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994
5. 5. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993
6. 6. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang H-G, Reed JC: Interaction among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 91: 9238-9242, 1994
7. 7. Sabourin JC, Martin A, Baruch J, True JB, Gompel A, Poitout P: Bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 59: 1-6, 1994
8. 8. Gee JMW, Robertson JFR, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI: Immuno-cytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994
9. 9. Wang TTY, Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487-2489, 1995
10. 10. Teixeira C, Reed JC, Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995
11. 11. Nenci I, Marchetti B, Querzoli P: Commentary on human mammary preneoplasia. The estrogen receptor-promotion hypothesis. J Steroid Biochem 30: 105-106, 1988
12. 12. Chabner BA, Longo DL: Cancer Chemotherapy, Second edition. Lippincott-Raven, Philadelphia, 1996
13. 13. Herr I, Wilhelm D, Bohler T, Angel P, Debatin KM: Activation of CD95 (APO1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 16: 6200-6208, 1997
14. 14. McGahon AJ, Costa Pereira AP, Daly L, Cotter TG: Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 101: 539-547, 1998
15. 15. Goldwasser F, Bae I, Fornace AJ Jr, Pommier Y: Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Oncol Res 8: 317-323, 1996
16. 16. Jaattela M, Benedict M, Tewari M, Shayman JA, Dixit VM: Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 10: 2297-2305, 1995
17. 17. Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE: Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry 26: 3776-3781, 1987
18. 18. Haldar S, Chintapalli J, Croce CM: Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996
19. 19. Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, Lamszus K, Goldberg ID, Rosen EM: Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Oncogene 16: 2229-2241, 1998
20. 20. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D: Immediate early up-regulation of Bax expression by p53 but not TGF beta I: a paradigm for distinct apoptotic pathways. Oncogene 9: 1791-1798, 1994
21. 21. Adams JM, Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1325, 1998
22. 22. Fornari FA Jr, Jarvis WD, Grant S, Orr MS, Randolph JK, White FK, Mumaw VR, Lovings ET, Freeman RH, Gewirtz DA: Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ 5: 723-733, 1994
23. 23. Fornari FA Jr, Jarvis DW, Grant S, Orr MS, Randolph JK, White FK, Gewirtz DA: Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol 51: 931-940, 1996
24. 24. Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C: Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemother Pharmacol 20: 305-310, 1987
25. 25. Piche A, Grim J, Rancourt C, Gomez-Navarro J, Reed JC, Curiel DT: Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 58: 2134-2140, 1998